We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$42M
This Fund
S&P 500
This Quarter
Est. Return
+14.5%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$340M
AUM Growth
+$94.6M
(+39%)
Cap. Flow
+$76.8M
Cap. Flow
% of AUM
22.61%
Top 10 Holdings %
Top 10 Hldgs %
47.34%
Holding
100
New
32
Increased
8
Reduced
12
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$16.1M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$12.2M |
| 3 |
Corbus Pharmaceuticals
CRBP
|
+$9.98M |
| 4 |
Glaukos
GKOS
|
+$9.58M |
| 5 |
Arrowhead Research
ARWR
|
+$8.66M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALIM
Alimera Sciences
ALIM
|
+$12M |
| 2 |
argenx
ARGX
|
+$9.89M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$6.82M |
| 4 |
Insmed
INSM
|
+$4.43M |
| 5 |
MoonLake Immunotherapeutics
MLTX
|
+$3.51M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.3% |
| 2 | Consumer Discretionary | 1.17% |
| 3 | Consumer Staples | 0.08% |
| 4 | Industrials | 0.03% |
| 5 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Xtant Medical Holdings
XTNT
$62.1M
| $5.01M | 1.48% |
7,415,413
| – | – |
|
27
Larimar Therapeutics
LRMR
$436M
| $4.54M | 1.34% |
693,000
| – | – |
|
28
Capricor Therapeutics
CAPR
$242M
| $4.33M | 1.28% |
+285,000
| New | +$1.41M |
|
29
Pulmonx
LUNG
$88M
| $4.14M | 1.22% |
+500,000
| New | +$3.62M |
|
|
30
Corbus Pharmaceuticals
CRBP
$180M
| $4.02M | 1.18% |
+195,000
| New | +$9.98M |
|
31
Keros Therapeutics
KROS
$211M
| $4.01M | 1.18% |
+69,000
| New | +$3.41M |
|
32
The RealReal
REAL
$1.54B
| $3.99M | 1.17% |
1,270,000
+19,762
| +2% | +$59.4K |
|
33
Perspective Therapeutics
CATX
$339M
| $3.87M | 1.14% |
290,000
+98,550
| +51% | +$1.31M |
|
34
Biohaven
BHVN
$2.17B
| $3.75M | 1.1% |
+75,000
| New | +$2.92M |
|
35
Oric Pharmaceuticals
ORIC
$1.34B
| $3.64M | 1.07% |
355,000
-50,000
| -12% | -$494K |
|
36
Structure Therapeutics
GPCR
$3.74B
| $3.07M | 0.9% |
+70,000
| New | +$2.71M |
|
37
Outlook Therapeutics
OTLK
$182M
| $2.89M | 0.85% |
541,549
+39,764
| +8% | +$291K |
|
38
Vericel Corp
VCEL
$2.29B
| $2.87M | 0.85% |
+68,000
| New | +$3.24M |
|
|
HELP
39
Cybin Inc
HELP
$688M
| $2.82M | 0.83% |
317,000
-50,197
| -14% | -$497K |
|
|
TERN
40
DELISTED
Terns Pharmaceuticals
TERN
| $2.75M | 0.81% |
+330,000
| New | +$2.72M |
|
41
Ocugen
OCGN
$420M
| $2.33M | 0.69% |
+2,350,000
| New | +$3.23M |
|
|
42
MoonLake Immunotherapeutics
MLTX
$1.53B
| $2.02M | 0.59% |
40,000
-75,000
| -65% | -$3.51M |
|
|
BCYC
43
Bicycle Therapeutics
BCYC
$278M
| $1.92M | 0.57% |
+85,000
| New | +$1.96M |
|
44
PUT
Annovis Bio
ANVS
$79.1M
| $1.91M | 0.56% |
236,400
+81,100
| +52% | +$760K |
|
45
Veru
VERU
$37.1M
| $1.56M | 0.46% |
202,853
-24,816
| -11% | -$214K |
|
46
AtriCure
ATRC
$2.01B
| $1.51M | 0.45% |
+54,000
| New | +$1.33M |
|
|
47
CALL
Larimar Therapeutics
LRMR
$436M
| $1.28M | 0.38% |
196,000
| – | – |
|
48
CytomX Therapeutics
CTMX
$734M
| $1.08M | 0.32% |
+915,000
| New | +$1.16M |
|
|
NVNO
49
enVVeno Medical
NVNO
$6.78M
| $803K | 0.24% |
+6,826
| New | +$1.25M |
|
50
Tempest Therapeutics
TPST
$14.4M
| $763K | 0.22% |
+41,923
| New | +$859K |
|
Similar funds
TA
SIM
VEPM
VI
BCM
VAM
SCM
CAS
Altium Capital Management's Q3 2024 Portfolio in Review
As of Q3 2024, Altium Capital Management held 100 positions worth $340M, up 39% from $245M the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Altium Capital Management deployed $76.8M of net new capital in Q3 2024, opening 32 new positions and adding to 8 existing holdings. Its largest new stake was Edwards Lifesciences: 222,000 shares worth $14.6M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
On the sell side, the largest reduction was Insmed, an estimated $4.43M trimmed.
- Altium Capital Management's largest Q3 2024 buy was Edwards Lifesciences: 222,000 shares worth $14.6M.
- Altium Capital Management added most to Sarepta Therapeutics in Q3 2024, an estimated $12.2M increase.
- Altium Capital Management's biggest Q3 2024 reduction was Insmed, cutting an estimated $4.43M.
- Altium Capital Management fully exited Alimera Sciences in Q3 2024, selling an estimated $12M.
- Altium Capital Management's ten largest holdings make up 47% of its $340M portfolio in Q3 2024.
- Altium Capital Management opened 32 new positions and closed 21 in Q3 2024.
- Altium Capital Management's portfolio value rose 39% quarter-over-quarter to $340M.
Based on Altium Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.